Related references
Note: Only part of the references are listed.Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis
Mangala Kumari et al.
NUTRIENTS (2021)
Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease
Duygu Turan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Protective role of caffeic acid in an Aβ25-35-induced Alzheimer's disease model
Ji Hyun Kim et al.
NUTRITION RESEARCH AND PRACTICE (2015)
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease
John E. Kelsey et al.
PSYCHOPHARMACOLOGY (2014)
An economic model of Parkinson's disease: Implications for slowing progression in the United States
Scott J. Johnson et al.
MOVEMENT DISORDERS (2013)
CAFFEIC ACID PHENETHYL ESTER PROTECTS AGAINST THE DOPAMINERGIC NEURONAL LOSS INDUCED BY 6-HYDROXYDOPAMINE IN RATS
R. Barros Silva et al.
NEUROSCIENCE (2013)
Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile
Hai Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson's Disease
Vija Z. Klusa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2010)
Pharmacokinetics of Caffeic Acid Phenethyl Ester and its Catechol-ring Fluorinated Derivative Following Intravenous Administration to Rats
Xinyu Wang et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2009)
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease
Lilia Marinova-Mutafchieva et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Effects of age and anxiety on learning and memory
Ayseguel Kuecuek et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Beating a dead horse - Dopamine and Parkinson disease
J. Eric Ahlskog
NEUROLOGY (2007)
Caffeic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia
Mushfiquddin Khan et al.
JOURNAL OF NEUROCHEMISTRY (2007)
In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis
Nicola Celli et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2007)
Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity
Zhizhong Ma et al.
LIFE SCIENCES (2006)
An improved test of neurological dysfunction following transient focal cerebral ischemia in rats
ME Sughrue et al.
JOURNAL OF NEUROSCIENCE METHODS (2006)
Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels
Shih-Jen Tsai
MEDICAL HYPOTHESES (2006)
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma
B Li et al.
BIOCHEMICAL PHARMACOLOGY (2005)
The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity
C Noelker et al.
NEUROSCIENCE LETTERS (2005)
Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats
A Ilhan et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury
X Wei et al.
BRAIN (2004)
Free radical scavenging and antioxidative activity of caffeic acid amide and ester analogues: Structure-activity relationship
S Son et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2002)